NEW YORK, Nov. 9, 2005 (PRIMEZONE) -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(r) (EIO(r)) on Vancouver-based MIGENIX Inc. (TSX:MGI) (Other OTC:MGIFF). The full 44-page report can be found at www.crystalra.com, or through a link located in the Investor Relations section of the MIGENIX web site at www.migenix.com. This report was paid for by MIGENIX.
MIGENIX is a biopharmaceutical company engaged in the research, development, and commercialization of products primarily in the area of infectious diseases. The Company is developing compounds from the post-discovery stage through to late-stage clinical development. MIGENIX's pipeline currently features a balanced portfolio, which contains several preclinical to Phase III product candidates to treat chronic Hepatitis C Virus (HCV) infections (Phase II and preclinical candidates); to prevent catheter-related infections (Phase III); to treat gram-positive bacterial infections (preclinical); and to treat acne (Phase II). In August 2004, MIGENIX acquired MitoKor, Inc., a San Diego-based private biotechnology firm, providing MIGENIX with several promising clinical and preclinical product candidates to treat major medical conditions related to mitochondrial dysfunction and further bolstering the Company's pipeline. Candidates are under evaluation for indications such as Friedreich's ataxia, retinitis pigmentosa (RP), arthritis, and others.
MIGENIX is listed on the Toronto Stock Exchange (TSX) under the symbol MGI and the OTC under the symbol MGIFF. The Company is headquartered in Vancouver, B.C., Canada, with U.S. operations in San Diego, California.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality fee-based research to small and mid-cap companies. The Company's unique and novel product, the Executive Informational Overview(r) (EIO(r)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(r) presents a crystal-clear, detailed report on a company (whether public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(r) details a company's product/technology/service offerings, market size(s), key intellectual property (IP), leadership, growth strategy, competition, risks, audited financial statements, key events and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Please see back of report for complete Company disclosures.
Forward-Looking Safe Harbor Statement
To the extent that this release discusses any expectations concerning future plans, financial results or performance, such statements are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and are subject to substantial risks and uncertainties. Actual results could differ materially from those anticipated in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and reflect only management's belief and expectations based upon presently available information. These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates, LLC assumes no obligation to update any of the forward-looking statements in this release.